Health Condition 1: H353- Degeneration of macula and posterior pole Health Condition 2: I10- Essential (primary) hypertension Health Condition 3: E106- Type 1 diabetes mellitus with other specified complications Health Condition 4: E116- Type 2 diabetes mellitus with other specified complications
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1 Adults aged eighteen years and above with a known diagnosis of hypertension or currently taking antihypertensive medication. 2 Adults aged eighteen years and above with a documented diagnosis of hypertension, defined as: Stage 1 Hypertension: Systolic blood pressure between one hundred thirty and one hundred thirty-nine millimetres of mercury or diastolic blood pressure between eighty and eighty-nine millimetres of mercury. Stage 2 Hypertension: Systolic blood pressure of one hundred forty millimetres of mercury or higher, or diastolic blood pressure of ninety millimetres of mercury or higher. 3 Adults aged eighteen years and above with a known diagnosis of type 1 diabetes mellitus for at least five years. 4 Adults aged eighteen years and above with a known or newly diagnosed case of type 2 diabetes mellitus. 5 Newly diagnosed individuals meeting at least one of the following criteria: Fasting Plasma Glucose of one hundred twenty-five milligrams per decilitre or higher. Two-hour plasma glucose after seventy-five grams oral glucose load of two hundred milligrams per decilitre or higher. Random Blood Sugar of two hundred milligrams per decilitre or higher. Glycated haemoglobin (HbA1c) of six point five percent or higher. 6 Individuals with both diabetes and hypertension will not be included. 7 Adults aged fifty years and above, irrespective of known chronic disease status, for screening of age-related macular degeneration.
Exclusion criteria
Exclusion criteria: 1 Eyes with media opacities, such as dense cataract, that make it impossible to visualize the retina. 2 Participants already diagnosed and currently undergoing active treatment for retinal conditions, such as those who have previously received laser therapy, intravitreal injections, or retinal surgery.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evidence on Implementation outcomes: acceptability, feasibility, sustainability, fidelity of CHO led smartphone-based DR screening of Hypertensive Retinopathy (HR), and Age-Related Macular Degeneration (ARMD). Benefits of the Implementation System-level recommendations for scale-up Timepoint: 3 months | — |
Secondary
| Measure | Time frame |
|---|---|
| NILTimepoint: NIL | — |
Countries
India
Contacts
ICMR-RMRCBB